Compare CLST & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | BDSX |
|---|---|---|
| Founded | 1922 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | CLST | BDSX |
|---|---|---|
| Price | $15.03 | $8.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 6.6K | ★ 61.9K |
| Earning Date | 01-22-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | $11,340,000.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $19.04 |
| Revenue Next Year | N/A | $26.39 |
| P/E Ratio | $25.23 | ★ N/A |
| Revenue Growth | ★ 133.67 | 22.29 |
| 52 Week Low | $10.67 | $3.44 |
| 52 Week High | $15.30 | $32.20 |
| Indicator | CLST | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 61.18 |
| Support Level | $15.00 | $7.68 |
| Resistance Level | $15.00 | $8.17 |
| Average True Range (ATR) | 0.09 | 0.65 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 95.56 | 96.40 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.